{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:25:58Z","timestamp":1795029958916,"version":"4.10.2"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nanoparticles can potentially stimulate tumour microenvironments to elicit antitumour immunity. Herein, we demonstrate effective immunotherapy of colorectal cancer via systemic delivery of an immunostimulatory chemotherapeutic combination in nanoscale coordination polymer (NCP) core-shell particles. Oxaliplatin and dihydroartemesinin have contrasting physicochemical properties but strong synergy in reactive oxygen species (ROS) generation and anticancer activity. The combined ROS generation is harnessed for immune activation to synergize with an anti-PD-L1 antibody for the treatment of murine colorectal cancer tumours. The favourable biodistribution and tumour uptake of NCPs and the absence of peripheral neuropathy allow for repeated dosing to afford 100% tumour eradication. The involvement of innate and adaptive immune systems elicit strong and long lasting antitumour immunity which prevents tumour formation when cured mice are challenged with cancer cells. The intrinsically biodegradable, well tolerated, and systemically available immunostimulatory NCP promises to enter clinical testing as an immunotherapy against colorectal cancer.<\/jats:p>","DOI":"10.1038\/s41467-019-09221-x","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T06:04:03Z","timestamp":1555999443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":236,"title":["Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors"],"prefix":"10.1038","volume":"10","author":[{"given":"Xiaopin","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nining","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph R.","family":"Weichselbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7035-7759","authenticated-orcid":false,"given":"Wenbin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"9221_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5\u201329 (2015).","journal-title":"CA Cancer J. Clin."},{"key":"9221_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1080\/07357900802132550","volume":"26","author":"S Sharif","year":"2008","unstructured":"Sharif, S., O\u2019Connell, M. J., Yothers, G., Lopa, S. & Wolmark, N. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest. 26, 956\u2013963 (2008).","journal-title":"Cancer Invest."},{"key":"9221_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1200\/JCO.2013.53.5195","volume":"32","author":"KV Loon","year":"2014","unstructured":"Loon, K. V. & Venook, A. P. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities. J. Clin. Oncol. 32, 991\u2013996 (2014).","journal-title":"J. Clin. Oncol."},{"key":"9221_CR4","first-page":"301","volume":"15","author":"B Xiang","year":"2013","unstructured":"Xiang, B., Snook, A. E., Magee, M. S. & Waldman, S. A. Colorectal cancer immunotherapy. Discov. Med. 15, 301\u2013308 (2013).","journal-title":"Discov. Med."},{"key":"9221_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1470-2045(00)00034-6","volume":"1","author":"R Midgley","year":"2000","unstructured":"Midgley, R. & Kerr, D. Immunotherapy for colorectal cancer: a challenge to clinical trial design. Lancet Oncol. 1, 159\u2013168 (2000).","journal-title":"Lancet Oncol."},{"key":"9221_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/471561a","volume":"471","author":"H Ledford","year":"2011","unstructured":"Ledford, H. Melanoma drug wins US approval. Nature 471, 561 (2011).","journal-title":"Nature"},{"key":"9221_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/OTT.S153056","volume":"11","author":"B Fleisher","year":"2018","unstructured":"Fleisher, B. & Ait-Oudhia, S. A retrospective examination of the US Food and Drug Administration\u2019s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring. Onco. Targets Ther. 11, 113\u2013121 (2018).","journal-title":"Onco. Targets Ther."},{"key":"9221_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab, H. O. et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front. Pharmacol. 8, 561 (2017).","journal-title":"Front. Pharmacol."},{"key":"9221_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa, N. J. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5, 43\u201351 (2015).","journal-title":"Cancer Discov."},{"key":"9221_CR10","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"9221_CR11","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.2016.34.15_suppl.3501","volume":"34","author":"MJ Overman","year":"2016","unstructured":"Overman, M. J. et al. Nivolumab\u2009\u00b1\u2009ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J. Clin. Oncol. 34, 3501\u20133501 (2016).","journal-title":"J. Clin. Oncol."},{"key":"9221_CR12","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182\u20131191 (2017).","journal-title":"Lancet Oncol."},{"key":"9221_CR13","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","volume":"138","author":"CR Boland","year":"2010","unstructured":"Boland, C. R. & Goel, A. Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073\u20132087 e2073 (2010).","journal-title":"Gastroenterology"},{"key":"9221_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrclinonc.2009.237","volume":"7","author":"E Vilar","year":"2010","unstructured":"Vilar, E. & Gruber, S. B. Microsatellite instability in colorectal cancer\u2014the stable evidence. Nat. Rev. Clin. Oncol. 7, 153\u2013162 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"9221_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","volume":"44","author":"PJR Ebert","year":"2016","unstructured":"Ebert, P. J. R. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity 44, 609\u2013621 (2016).","journal-title":"Immunity"},{"key":"9221_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482\u2013491 (2010).","journal-title":"Oncogene"},{"key":"9221_CR17","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato, E. et al. Intraepithelial CD8\u2009+\u2009tumor-infiltrating lymphocytes and a high CD8\u2009+\u2009\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102, 18538\u201318543 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9221_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/gut.2010.211722","volume":"60","author":"M Gonzalez-Aparicio","year":"2011","unstructured":"Gonzalez-Aparicio, M. et al. Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut 60, 341\u2013349 (2011).","journal-title":"Gut"},{"key":"9221_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/onci.1.1.17930","volume":"1","author":"R Hernandez-Alcoceba","year":"2012","unstructured":"Hernandez-Alcoceba, R. & Berraondo, P. Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin. Oncoimmunology 1, 97\u201399 (2012).","journal-title":"Oncoimmunology"},{"key":"9221_CR20","doi-asserted-by":"publisher","first-page":"12499","DOI":"10.1038\/ncomms12499","volume":"7","author":"C He","year":"2016","unstructured":"He, C. et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat. Commun. 7, 12499 (2016).","journal-title":"Nat. Commun."},{"key":"9221_CR21","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/nm.2471","volume":"17","author":"Y Tu","year":"2011","unstructured":"Tu, Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 17, 1217\u20131220 (2011).","journal-title":"Nat. Med."},{"key":"9221_CR22","doi-asserted-by":"publisher","first-page":"7606","DOI":"10.1074\/jbc.M112.424655","volume":"288","author":"SE Thomas","year":"2013","unstructured":"Thomas, S. E. et al. p53 and translation attenuation regulate distinct cell cycle checkpoints during endoplasmic reticulum (ER) stress. J. Biol. Chem. 288, 7606\u20137617 (2013).","journal-title":"J. Biol. Chem."},{"key":"9221_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54\u201361 (2007).","journal-title":"Nat. Med."},{"key":"9221_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nri2545","volume":"9","author":"DR Green","year":"2009","unstructured":"Green, D. R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9, 353\u2013363 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"9221_CR25","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","volume":"16","author":"L Zitvogel","year":"2010","unstructured":"Zitvogel, L. et al. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin. Cancer Res. 16, 3100\u20133104 (2010).","journal-title":"Clin. Cancer Res."},{"key":"9221_CR26","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15, 1170\u20131178 (2009).","journal-title":"Nat. Med."},{"key":"9221_CR27","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209\u20131215 (2015).","journal-title":"Nat. Med."},{"key":"9221_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nrclinonc.2015.131","volume":"12","author":"E Munzone","year":"2015","unstructured":"Munzone, E. & Colleoni, M. Clinical overview of metronomic chemotherapy in breast cancer. Nat. Rev. Clin. Oncol. 12, 631\u2013644 (2015).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"9221_CR29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/ncponc0560","volume":"3","author":"R Simon","year":"2006","unstructured":"Simon, R. & Norton, L. The Norton\u2212Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat. Clin. Pract. Oncol. 3, 406\u2013407 (2006).","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"9221_CR30","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1002\/eji.201242480","volume":"42","author":"C Hespel","year":"2012","unstructured":"Hespel, C. & Moser, M. Role of inflammatory dendritic cells in innate and adaptive immunity. Eur. J. Immunol. 42, 2535\u20132543 (2012).","journal-title":"Eur. J. Immunol."},{"key":"9221_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0952-7915(97)80153-7","volume":"9","author":"M Cella","year":"1997","unstructured":"Cella, M., Sallusto, F. & Lanzavecchia, A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9, 10\u201316 (1997).","journal-title":"Curr. Opin. Immunol."},{"key":"9221_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","volume":"106","author":"I Mellman","year":"2001","unstructured":"Mellman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255\u2013258 (2001).","journal-title":"Cell"},{"key":"9221_CR33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.iy.02.040184.002143","volume":"2","author":"ER Unanue","year":"1984","unstructured":"Unanue, E. R. Antigen-presenting function of the macrophage. Annu. Rev. Immunol. 2, 395\u2013428 (1984).","journal-title":"Annu. Rev. Immunol."},{"key":"9221_CR34","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1084\/jem.179.4.1331","volume":"179","author":"AS McWilliam","year":"1994","unstructured":"McWilliam, A. S., Nelson, D., Thomas, J. A. & Holt, P. G. Rapid dendritic cell recruitment is a hallmark of the acute inflammatory response at mucosal surfaces. J. Exp. Med. 179, 1331\u20131336 (1994).","journal-title":"J. Exp. Med."},{"key":"9221_CR35","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974\u20131982 (2015).","journal-title":"J. Clin. Oncol."},{"key":"9221_CR36","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/jco.2015.33.15_suppl.3001","volume":"33","author":"A Ribas","year":"2015","unstructured":"Ribas, A. et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J. Clin. Oncol. 33, 3001\u20133001 (2015).","journal-title":"J. Clin. Oncol."},{"key":"9221_CR37","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827\u2013837 (2016).","journal-title":"Cancer Discov."},{"key":"9221_CR38","doi-asserted-by":"publisher","first-page":"956","DOI":"10.3109\/1061186X.2013.837470","volume":"21","author":"JY Ljubimova","year":"2013","unstructured":"Ljubimova, J. Y. et al. Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment. J. Drug Target. 21, 956\u2013967 (2013).","journal-title":"J. Drug Target."},{"key":"9221_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jconrel.2016.11.005","volume":"244","author":"Y Xiong","year":"2016","unstructured":"Xiong, Y., Zhao, Y., Miao, L., Lin, C. M. & Huang, L. Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J. Control Release 244, 63\u201373 (2016).","journal-title":"J. Control Release"},{"key":"9221_CR40","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.ymthe.2017.04.026","volume":"25","author":"S Quader","year":"2017","unstructured":"Quader, S. & Kataoka, K. Nanomaterial-enabled cancer therapy. Mol. Ther. 25, 1501\u20131513 (2017).","journal-title":"Mol. Ther."},{"key":"9221_CR41","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.2217\/nnm.15.86","volume":"10","author":"E Huynh","year":"2015","unstructured":"Huynh, E. & Zheng, G. Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Nanomed. (Lond.) 10, 1993\u20131995 (2015).","journal-title":"Nanomed. (Lond.)"},{"key":"9221_CR42","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1021\/nn500299p","volume":"8","author":"EA Sykes","year":"2014","unstructured":"Sykes, E. A., Chen, J., Zheng, G. & Chan, W. C. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano 8, 5696\u20135706 (2014).","journal-title":"ACS Nano"},{"key":"9221_CR43","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1021\/acs.molpharmaceut.6b00219","volume":"13","author":"R Taniguchi","year":"2016","unstructured":"Taniguchi, R. et al. Adequately-sized nanocarriers allow sustained targeted drug delivery to neointimal lesions in rat arteries. Mol. Pharm. 13, 2108\u20132116 (2016).","journal-title":"Mol. Pharm."},{"key":"9221_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nnano.2009.314","volume":"5","author":"HS Choi","year":"2010","unstructured":"Choi, H. S. et al. Design considerations for tumour-targeted nanoparticles. Nat. Nanotechnol. 5, 42\u201347 (2010).","journal-title":"Nat. Nanotechnol."},{"key":"9221_CR45","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"ME Davis","year":"2008","unstructured":"Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771\u2013782 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9221_CR46","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1126\/science.1095833","volume":"303","author":"TM Allen","year":"2004","unstructured":"Allen, T. M. & Cullis, P. R. Drug delivery systems: entering the mainstream. Science 303, 1818\u20131822 (2004).","journal-title":"Science"},{"key":"9221_CR47","doi-asserted-by":"publisher","first-page":"11109","DOI":"10.1021\/acs.chemrev.5b00109","volume":"115","author":"DJ Irvine","year":"2015","unstructured":"Irvine, D. J., Hanson, M. C., Rakhra, K. & Tokatlian, T. Synthetic nanoparticles for vaccines and immunotherapy. Chem. Rev. 115, 11109\u201311146 (2015).","journal-title":"Chem. Rev."},{"key":"9221_CR48","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1021\/acs.bioconjchem.6b00483","volume":"27","author":"AB Chinen","year":"2016","unstructured":"Chinen, A. B., Ferrer, J. R., Merkel, T. J. & Mirkin, C. A. Relationships between poly(ethylene glycol) modifications on RNA-spherical nucleic acid conjugates and cellular uptake and circulation time. Bioconjug. Chem. 27, 2715\u20132721 (2016).","journal-title":"Bioconjug. Chem."},{"key":"9221_CR49","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1021\/acsnano.7b08148","volume":"12","author":"H Jin","year":"2018","unstructured":"Jin, H. et al. Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel. ACS Nano 12, 3295\u20133310 (2018).","journal-title":"ACS Nano"},{"key":"9221_CR50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.canlet.2016.05.025","volume":"379","author":"Y Lu","year":"2016","unstructured":"Lu, Y. et al. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: a combination nanomedicine approach. Cancer Lett. 379, 32\u201338 (2016).","journal-title":"Cancer Lett."},{"key":"9221_CR51","doi-asserted-by":"publisher","first-page":"1702909","DOI":"10.1002\/smll.201702909","volume":"14","author":"B Meckes","year":"2018","unstructured":"Meckes, B. & Banga, R. J. & Nguyen, S. T. & Mirkin, C. A. Enhancing the stability and immunomodulatory activity of liposomal spherical nucleic acids through lipid-tail DNA modifications. Small 14, 1702909 (2018).","journal-title":"Small"},{"key":"9221_CR52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.biomaterials.2016.04.008","volume":"95","author":"X Luan","year":"2016","unstructured":"Luan, X. et al. Tumor priming using metronomic chemotherapy with neovasculature-targeted, nanoparticulate paclitaxel. Biomaterials 95, 60\u201373 (2016).","journal-title":"Biomaterials"},{"key":"9221_CR53","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"9221_CR54","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/sj.cdd.4402201","volume":"14","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 14, 1848\u20131850 (2007).","journal-title":"Cell Death Differ."},{"key":"9221_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1600-065X.2007.00573.x","volume":"220","author":"L Apetoh","year":"2007","unstructured":"Apetoh, L. et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220, 47\u201359 (2007).","journal-title":"Immunol. Rev."},{"key":"9221_CR56","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050\u20131059 (2007).","journal-title":"Nat. Med."},{"key":"9221_CR57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51\u201372 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"9221_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","volume":"5","author":"SI Mosely","year":"2017","unstructured":"Mosely, S. I. et al. Rational selection of syngeneic preclinical tumor odels for immunotherapeutic drug discovery. Cancer Immunol. Res 5, 29\u201341 (2017).","journal-title":"Cancer Immunol. Res"},{"key":"9221_CR59","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/j.vaccine.2017.03.067","volume":"35","author":"TJ Goodwin","year":"2017","unstructured":"Goodwin, T. J. & Huang, L. Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis. Vaccine 35, 2550\u20132557 (2017).","journal-title":"Vaccine"},{"key":"9221_CR60","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja, V. R. et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J. Exp. Med. 214, 895\u2013904 (2017).","journal-title":"J. Exp. Med."},{"key":"9221_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5182","volume":"5","author":"D Liu","year":"2014","unstructured":"Liu, D., Poon, C., Lu, K., He, C. & Lin, W. Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat. Commun. 5, 4182 (2014).","journal-title":"Nat. Commun."},{"key":"9221_CR62","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.14440\/jbm.2014.12","volume":"1","author":"A Madaan","year":"2014","unstructured":"Madaan, A., Verma, R., Singh, A. T., Jain, S. K. & Jaggi, M. A stepwise procedure for isolation of murine bone marrow and generation of dendritic cells. J. Biol. Methods 1, e1 (2014).","journal-title":"J. Biol. Methods"},{"key":"9221_CR63","doi-asserted-by":"crossref","first-page":"14.1.11","DOI":"10.1002\/0471142735.im1401s111","volume":"111","author":"R Gon\u00e7alves","year":"2015","unstructured":"Gon\u00e7alves, R. & Mosser, D. M. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. 111, 14.1.11\u201314.1.16 (2015).","journal-title":"Curr. Protoc. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09221-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09221-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09221-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T17:59:40Z","timestamp":1671213580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09221-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["9221"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-09221-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]},"assertion":[{"value":"17 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.L. is the founder of Coordination Pharmaceuticals, Inc., which licenses the NCP technology from the University of Chicago. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1899"}}